Official TitleA Phase 3, Randomized, 24-week, Placebo-controlled, Double-blind Study to Assess the Efficacy, Safety and Tolerability of Rocatinlimab (AMG 451) Monotherapy in Adult
Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-Horizon)
The purpose of this study is to evaluate the efficacy of rocatinlimab.
Could this study be right for you?
- Subject must have a diagnosis of atopic dermatitis for a least 6 months prior to study visit
- Subject must have tried a topical medication with little to no improvement
- Subject must be in good general health with no history of tuberculosis, heart disease, cancer, HIV, hepatitis B or C, or blood clots
- Female subjects must not be pregnant, breastfeeding, or considering becoming pregnant for the duration of the study
18 years and up